Aurinia Pharmaceuticals (AUPH) 4 Aug 222022 Q2 Earnings call transcript

Greetings, and welcome to Aurinia Pharmaceuticals Second Quarter 2022 Financial and Operational Results Conference Call. At this time all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host DeDe Sheel, Aurinia's Vice President of Investor Relations. you. Thank

begin. may You

and to all XXXX discuss Doug, call financial joining and webcast Aurinia's thank you, for you today's results. Thank second quarter

Peter our the Joe this President Medical Dr. Officer, me morning be lead Chief call Joining available also at to Neil Solomons, our prepared quarterly and of highlights issued a Chief Miller, are CEO; we remarks This call. morning operational XX-Q. Form for will our on Financial recent release report the financial conclusion Officer. the announcing the and and Q&A filed portion Greenleaf, of results press

For on please to our the with available auriniapharma.com. more at information, our SEC, filings website are refer which U.S.

are uncertainties, forward-looking significant may call, During subject based and this a statements make statements risks results number our of materially. our may differ current actual and on we to expectations. forward-looking These

such unless our note upon on noted as that statements please quarterly press and of report that factors today's XXXX, the refer For of during and are SEC along and statements. our as law, we this by Please required recent the to of to XX, Canadian any August are obligation all could release disclosures made to current business, filings discussion financial based us our with Form our available with update in affect Authorities. results XX-K information today, Except currently Securities call and at all otherwise our time. XX-Q, and no assume future

over President Peter? to and Aurinia's CEO, me Greenleaf. Let turn the Peter call now

today. joining thanks Thanks, to DeDe, and for us everyone

and quarter the the performance our positive opinion for I'll by to LUPKYNIS review us additional LUPKYNIS intellectual trends in we're Europe. today, recent our the a the benefits clinical of of related events that, the half for product work discuss ongoing call EMA discuss the second the reinforce entering approval recent of the for of cover briefly commercial year. in on I'll business, On with seeing including LUPKYNIS to and also the After patients putting second property. verge gaining the I'll the CHMP start

R&D details results a Finally, call more second update I'll and quarter on provide over on then our the the Joe to pipeline overall financial to financial provide turn and position. quick our

get let's our performance. started Total revenues contributing sales with business product for with $XX.X net the So million quarter second LUPKYNIS million. $XX.X were quarter

them quarter the persisted LUPKYNIS. we many of which first the encouraging supporting of with The of During trends second this into year, the quarter-over-quarter. commercial actually majority improving number of quarter saw a performance

we also to number trends the our patients saw trends at QX. months, XX% QX. the business product. of in in therapy We last since X,XXX shipped of a patients and on the and Persistency positive approximately some encouraging. months launch nine in notable wallets with XX% the the XX% highest remain quarter, treatment. of on rates are on quarter of six in approximately grew at patients of from Total improvements treatment commercial Consistent Here remain remain at saw refill X,XXX, end up

as per nephrologists. to mix as adding consistent on and both increase patient improve to figures new between more remain rates our on Each Prescribing continue rheumatologists all launch. prescribers practice go conversion revenue robust, these currently in LUPKYNIS further level are the and over adoption we update to initial we patient Conversion patients the on we're new as approach quarter into continue balanced expect rates XX,XXX to evolve. year. peak time will guidance remain and for an realizable continue per than we discussed, and payor two we XXX quarter is and prescribers since previously, of the and therapy Net regular annualized stay day rates access XX, with and alone. as previously it's launch. and discussed at Efforts XX But provider higher or As this progress and to positive. XX healthcare figure basis whether dosing remain of month, persistency

positive we're XXth. while less we're with PSFs, year-to-date for on total through a pleased we XXth In performance start XXX. number trends, PSFs So QX, July with quarter. updated of as XXX of total Friday, is forms those year-to-date pleased PSFs of our XXX our bringing prescription added the June to The

trends time, we've data that and assess Over the treatments and prescribing seen separate the physician the the that marketplace. lupus from habits exist to market, trends in nephritis and might in We patient further any the to have the journey, potential any we overall seasonality in want been historic seasonality analyzing community. the understand for annual COVID

we any treatments. As XXXX, seasonality, But goal a historically changes back to of was year deeper XXXX market that getting been lupus regardless of our patients. throughout lupus for retention that now prescription In trend to attacking with drove evaluate seasonality improving and variant on the business. need we trends positive know have will and impacting and the us we the form opportunities points calendar the impact know, year and COVID impact where we have overall of been our opportunities differences have are closed that investment start

medical representatives. Scott the following specialized lupus are Commercial and both of the and year we Max the intimate with Group are lupus nephritis both industry pharmaceutical our launch both were and Habig to the the We patients Under both leadership, with patient major Scott's prescriber – from We programs seasoned closed patients. to contains a the addition treatment with our Commercial as Officer lupus Scott industry focus that Chief and markets Colao. first base is in knowledge population. centers transition intensifying our veteran of of know lead excited

hold best have centers the access increased the to these candidates. these and great the focus to medical specialized with We our proper a lupus believe that of partner and screening diagnose During country treatment thinking patients our ability around early how QX, major programs. with nephritis centers number we around to that offer lupus lupus

months. the upcoming these So on we reporting impact over look to our forward centers in

an those increased In both terms and initiatives. emphasis of both to support driving based putting terms and efforts, patient retention patient of education, in awareness and in broad addition locally strategies, diagnosis nationally and on we're

and million With moving calendar the we of confident LUPKYNIS reaffirm more, improved execution guidance our leadership a net intense and these forward year we commercial QX. full an our place, focus with new to both initiatives remain QX and in for for to $XXX $XXX are PSFs and in goal in million on sales commercial of And growth XXXX.

of CHMP a Last a The company. again for Based adults LUPKYNIS for achieved by to depending outside recommended our decision the by favourability month, expected on recommendation, million. approved treat up the we payment with major U.S. LUPKYNIS is we formally potential the Otsuka the milestone approved is milestone approve Turning to have lupus on European end commission from the by EMA, a to outside XX to the to CHMP LUPKYNIS voclosporin to nephritis. label, Once authorization of the quarter. lupus the the marketing of third receive

through sales low the potential plus also going and we forward. cost cost royalties on double-digit a receive have addition, supply recovery arrangement to In

in does payments Japan. from revenue guidance our with revenue European or not agreement related to anticipated sales payment, market the ex-U.S. include manufacturing our Union Otsuka licensing reminder, a and this voclosporin As milestone royalty to

if quarter. continuing to the providers had soon. efforts. development to regard a report we we look our gears visibility broader outside Shifting to as you to work healthcare to With we we had to – the forward major our medical as our significant in related in U.S. two So R&D presence conferences progress LUPKYNIS, with

months we the at followed voclosporin at first the This of submit XXXX at in which for that meetings by additional XXth into During a publication efficacy over a trial. presentation the reinforces XXXX presented as AURORA XX-month the and And from continuation patients second an continuing European time period, more comparable QX, the reported quickly abstracts presentations December, well throughout reviewed Congress safety manuscript for major as AURORA We medical LUPKYNIS of and for European still peer benefit of complete treatment. results in This from profile study XXXX. from additional which favorable AURORA we the X XXXX, Rheumatology. both study three-year to data to pivotal plan was half risk at this original Association Congress. the study, XX seen for looked data Renal the in data

ENLIGHT-LN patients as REGISTRY both On to and is our topic improve to access and sites of the of about patients and to And the of pediatric the the part additional patient knowledge gain study we further work physicians LUPKYNIS, REGISTRY and initiated with while study recruitment news LUPKYNIS continuing. treated to the therapy. of we and payers to with study and vocal the committed reminder, a being vocal development initiation treatment to care help approval, as FDA ensure into

research to to growth INDs both out continue long-term in Moving advance to pipeline, on enabling our the remain on compounds we submit our IND and AURXXX build XXXX. next AURXXX, steps build track in both are for and for on we important These of to pipeline work the sustainable company.

relative final determination and – Inter this Partes its have could patent related of years granted, LUPKYNIS expected of Pharmaceuticals. week, notified when extension or our Regardless Office’s to the on prior we extends protocol to October XXXX. by outcomes patent that standard patent on Patent us decision U.S. Sun Appeal The the and As matter, announced filed extend terms through IPR Trade Board in to review patentability of composition subject for the IPR the the the A term IPR five XXXX. on to institute Patent XXXX. of July Trial a existing to is and to patent last protection extend which IPR, of trial XX, by or is if filed for dosing

intellectual have applications granted LUPKYNIS. other for property also if which offer protection additional We patent could underway,

ongoing. our In to take where our an against and allege continue intellectual their in In patent to intending infringement LUPKYNIS. on on ophthalmic we addition, remains property voclosporin cases, our are to Sun have solution action we rights protect lawsuit all Pharmaceuticals, for

to that of want highlight to and well turn I the debt there on companies before relative cash remain a obligations. to many balance with out or no hand over $XXX including peer of So we call almost our positioned significant million sheet, I biopharma healthy Joe,

at remain volatile, I’ll Joe least While answer our then years next financial of the the the Joe? for business for review a for more to the to quick few operations our end of results. Miller questions and have. and any can call to over I’ll capital flexible that now remain you environment. current and might And return at market recap difficult the to detailed call the turn markets fund we

everyone. good Peter, morning, and Thank you,

sales. related million and development $XXX.X XXXX commercial at and for had As and offset research decrease of commercial our XX, the XX, funding to in cash activities, years. XXXX. milestone, of activities, Total drug of and by XX, cash, $XX.X million manufacturing, achievement and supply, the operations, planned pipeline ended quarters continuing FDA XXXX, investments XX, was up receipts in our fund increase XXXX believe financial the that post XXXX. restricted LUPKYNIS few million a was packaging and activities ended net pipeline least funding revenue and for we an XX, June and of $X.X six the The $XX.X June our revenue December partially commitments, programs, the have resources to for XX, current June to for related months include and at June investment and equivalents next million from $XXX.X investing million approval operating primarily we in cash is We June infrastructure, sufficient million commercialization Total our cash respectively. payment advancement XXXX, conducting $X.X one-time compared a

for XX, million $XX.X in revenues net penetration and ended product XXXX were and in share-based XX, for million increase June to quarter XX, XXXX, well SG&A XX, ended our $XX.X improvements six revenue of related the the legal to June periods in SG&A XX, million and SG&A $X.X coupled respectively. Total $XX.X June quarters was and and a compensation compensation primarily to commercialization coupled months XXXX corporate $XX.X the $XXX,XXX AURXXX our the $X.X R&D of XX, expense in investment lupus in sales increase our expenses expense in general ended sales and for both $X.X periods approximately $X.X Gross due and AURXXX ended XXXX June ended XX, $XX.X XX, XX% months share-based and million June adjustments million months cost as matters XX, million compensation development XXXX will for to consistent XX, six months June million $X.X increase XX, for respectively. the and Our XXXX comparison June driving was the increase We related the respectively. six with and to operating and Revenue and the million and for an inclusive R&D XX, and primarily shared-based the for and $XXX,XXX quarter ended Further XXXX drivers Selling, ended June June attributed for nephritis comparison June of million were gross inclusive XX, million periods. an growth XXXX XXXX. programs. $XX.X expenses six for million. were explained XX, operating as be million for million margin expenses XXXX, XX% months compensation an breakdown XX, in were reserve. and ended of and compensation compensation periods the months and of June our for ended expenses The ended months operating or the increase were compensation for increase Cost increase were XX, XXXX. the key with of $X.X inclusive of June market XX, million, support is XXXX both respectively. in $XX.X of XXXX The $XXX.X $XX.X expense metrics. XXXX to inclusive in both expenses, $XX.X sales XX, expense, R&D an and and XXXX sales months expense for driver XXXX was XXXX LUPKYNIS. million for million XXXX. XX, fluctuations remain June months ended and three product June The Total June number ended forward. were six was and XX, $XX.X the the share-based XX, for June of XXXX consisted a June expense moment. million our XX, Non-cash ended XXXX. and quarter share-based million XXXX primarily $XXX.X for June that revenue, and for to million primary LUPKYNIS. ended to XXXX. revenue, a further of cost expense, six for June million compensation to for The XXXX $X infrastructure XXXX for SG&A XXXX XXXX Gross of XX%. June three expenses due months ended six margin XX, share-based six for quarters was of the of was $XX.X June ended June R&D million, the stock Non-cash safety both will XX, $XX.X share-based and XXXX, XX, XX, the June June administrative was expenses, share-based share-based Non-cash Cost June going and expenses compensation quarters believe approximately XXXX margin were respectively. respectively. expense XX, XX% was was and due fairly the and and Non-cash June in June

net a the compared common of $X.XX June Aurinia the common or quarter per XX, per million or June share, as XXXX. a $XX.X loss $XX for loss loss to recorded For million net XXXX, net ended $X.XX loss quarter XX, net share ended of

With some common $X.XX $XX.X million of six per loss ended common as loss June net Aurinia share, call months of XX, back that, share a six a to like loss the XX, the I’d For Peter? XXXX, million June Peter recorded or $XX.X ended loss net compared XXXX. months hand remarks. $X.XX or to over net closing to for for the per net

Joe. Thanks,

throughout heard driving on throughout we’ve the year. first capitalizing the remain the half As you LUPKYNIS work on of focused we done call, the in

possible two towards as AURXXX. for the quickly AURXXX milestones, our IND results, we’re pipeline the well in commercial Beyond novel to the assets as submission moving closer in and U.S. Europe, triggering moving additional approval potential for

which with a operate to on balance our healthy strategy. enable continue to us We long-term sheet, will execute

on to joining the for progresses. updating thank And forward today. items to you us these as everybody year on the Looking want call I

we So for will call the Operator? now open that, with questions.

question-and-answer and be this Thank a comes [Operator Instructions] gentlemen, Jefferies. question you. your Ladies at with conducting of session. question. we'll proceed Maury Our time first Raycroft the line with from Please

on [indiscernible] morning. good Maury. for This Hi, is

into to C&Is of generic issues the the half strategic So changes of how with like the like place major is for the in heading what tackle user expected are course now, of example, second one Scott that. some

Yes.

clarify and a answer what they've we closed was were of the question only all not the if additional have under to blocking us. from targets. two at couple of listen for My during level potential strategies lupus COVID high So be, to rep really the closed I There taking lower basic they been medical us, half to in centers the against or the years centers to major have initiatives mentioned closed regular clinics. we call. are know lupus the been major having Not organization been would major impact of commercial our the not majority XXXX, more last year? and the the One, because centers dispersed in the just We of that fairly these sort in care patients. our the tertiary both to on of larger that medical that question, and looking outside targets potential to to then leadership our of deployment refreshed penetration repeat back to targets are look new top at tackling everything know

become not there, interest how and but medical takes formulary product purchase these affairs think I major around how our hot patterns centers it a major centers. everyone more medical and medical different has to also because reps from to access So open these we because everything approach, and only put interact adoption purchasing within renewed energy centers these and

of major the optimistic to remain medical we new out generate these So potential really patient flow about centers.

over The ways. whether patients day, our put on patient that ensure and efforts retention, two keeping over feel time continues on you on we'll on down patient their the second patients and in areas time is, that six then get and new growth improve that by know, that XX – confident renewed month, is our be acquiring year. to we one we continue receive patients would to for year those retention and guidance that It's prescriptions. these working here to trajectory education a it And driven back business achieve

And settings? community up, it. academic in follow one are then seeing Got or you like, discontinuations more

Can sorry. I'm the you question? repeat

any the is unique to insights seeing discontinuation and are so settings more rate from the academic nine prescribers? So dropping you patient community on six have in if months, or you discontinuations

Since the Yes. from now center. coming of setting, out academic the are not the those majority right patients coming the are of our community, community patients

about in that's be we across at think academic the got it think would when that, whether the board, I look we persistency community. to the center or

Thank you.

Our the Please Securities. comes next question. from proceed Schwartz of SVB Joseph with your question with line

Will our all. you on for question Thank Joe. for This taking Hi is today.

start we saw a us but factor are for this lower was forms. at to one than other provide insights still any patient last the here year. play last a other quarter numbers year, Could impact? than dynamics Given seasonality on the what the you So bit

back as into other than these Thank of half you. this could numbers be should how thinking about of and kind a seasonality you contextualize year? the we help bit progress the we So us

Yes.

more at in is they combined growth, holiday, generally the look looking than is on to Christmas into at go lupus were Thanksgiving that in and we digit, just summertime which of the broad areas just So BENLYSTA, if first starting are lupus the you I nephritis and terms the nephritis quarter. where and low trends. look could deeper both do NRX little definition at that two that growth look those then reported as GSK very but obviously this a we're And trends, their seasonality we're not single and I and lupus NRX bit one mean was lower numbers and, even lupus was by at to

connection that – we and less know potentially patients physicians and is there that into So offices with those offices themselves. from patients engagement

time we had in had and time watching periods, year year because the quarter and at last So, have the end this quarter. Well, as we enter we similar seeing then don't it year Delta third those both we're last we period a in we're into the variant of and of the this Omicron those trend variant this year.

And ones programs areas, I during Alliance proactive which as our renewed in mentioned, incentive is can that our to calling Alliance there products have seeing on Aurinia ensure getting they're initiatives that driving program that it, we're So can this tell less their it's reflected outside The that is include what to would the side into is ensure they're I focus, you are other as in well. just we're in prescriptions. all and would in tactics everything refilling Aurinia watching it patients, I and messaging their certain office that it. you sales to, opted from engagement tell calls period of appear putting from the and ours physicians the trying even behind lupus force patient

QX you of and control growing can we're point saw PSF to get the guidance the both prescriptions as and that's So week QX range to every month. this in patients, we to new where our $XXX and everything trend and quarter. confident we we combination we million ensuring last and able retention quarter, sort we're of in trend I achieve and retention were doing at as got million. QX, $XXX of maximized that to to with why our a on quarter the come the every came achieve back and we that between get and have And be into mix growth PSFs guess numbers and the think try bend the it on QX I look we for will the in

Thank you. Great.

of proceed question. from comes the Arce HC your at Our question Wainwright. next line with Ed Please

congrats solid quarter Hi, good on headwinds. morning the and despite the

you Just know could, one the mind investors a with now. I lot me of if for is process IPR of Peter, top question

give as sense the confidence your unfolds there strength Just general process thoughts next wondering year Thanks. over some the just this could or us of if the patent of you XXX in so. and

of Thanks, Ed. to legal a in of fairly And about tell given. It's litigation the have to the you longevity our with our obviously, there. outside high we be we and mean been can't the of patents a I of but answer, we say issued. obviously have previously we will lot pertains the in I have degree tools prosecute not we've the intention have patents I can been to talk a patents. ensure we sure our active we our since defense to the every we've make don't utilize fully ton confidence patents enforce longevity on I of but strategies are about will all business open-ended IPR, can control sort in and to and

Okay, Joe. follow-up fair and for then enough one

COGS that gross about gross this the first quarter noticed – margins Just in the went quarter. from XX% on to margins the the down XX% or it

stable. Just think looks we earlier, going wondering said if some about I be to is forward think there it dynamics you should or

So forward? around what going expect Thanks. should level we

hand or – should yes, consistent within quarter, with we of kind Yes, I remain had I think, and Ed, saw sorry. what And Joe I'm fairly the year-to-date, kind highlighted it you of of stock inventory that safety to quick kind for our beyond. one-time XXXX and dated on launch levels validation a batches the from had reserve that we some of back and

see that and fairly the remain we'll of consistent. kind we So stripped numbers out that

Thanks. fantastic. Okay,

your Kim comes proceed with with of next Our question. Please from question Justin the line Oppenheimer.

Hi, patients and sort switch gears think retention to wanted to morning, those of taking numbers thanks long-term for and little about of out our beyond. and sort bit, questions. XXX as just with Maybe good you a

in months? updates the presumably X, available of we’ve had hearing if there to in coming what been has might six AURORA you One wondering just become interest any from terms biopsy an of over XX things been the data,

Yes. Two things.

know all First different our this, their you small actually, molecule six whether others biologic at process off, Justin. nine think and their that I I numbers if like, what report benchmark and we retention versus But looks retain you and try benchmark persistency for in both it we and months diseases, individual percentage patient, as to we everything higher the work. Aurinia education terms to numbers. our alliance strategies patient to and to in down [ph] of broad-based enact place that have with percentages to even But well aspired AURORA and do

end and has here continues terms because biopsy data a said, at. at look a be I’ve way it looked AURORA there’s of you In data, to the we patients miss Neil both there And anything. the if of to said scrutinized And small that I’ve jump be But subset previously, the something to that too, study. was way, of I to continues be reviewed. here as as always Neil, think biopsy in should in I that

you So Neil, of going time, and reflect to ready just for that? prime data to all we when if we add would a end what this be of probably small should patients. have it’s that

of there’s histology we'll only report interesting had be exactly procurements is which Yes, patients data fewer back looked have a as more and get Peter. being when biopsies not the as XX% also away, work small no, repeat There’s on being some would we right, well, than that. sent that’s some up. to But samples

great. Okay, prior to we follow-up question. And just great, a a Thanks.

scripts. to and level assumption of and what the about of sort would XQ Is that, you end? sort that going change guidance it low right that sort there? of you that is way to guidance, end kind makes that the – thinking back the how What in low terms takes reach you In talk that was scripts, pace about assuming guidance, maybe about stable like, qualitatively think of of comfortable could of kind maybe of with to no of, what of revert like

Yes.

get So but see slight prescription beyond. what is, date it couldn’t the in we for need and hit And get first, second and see reaffirmed back And to and and in to fully will XXXX to a we I guidance wouldn’t to improvements has how to not would intention range. QX seen felt growth and that QX, if continue we that’s have start potentially just been for that price of one, we’ve that we the for the what there important trajectory, a up basis. assume say net adjust we our we annualized of types this forms alongside

So those it’s of all components, Justin.

so Thanks. great. much. Thanks Okay,

Olivia question Brayer comes of with Fitzgerald. your next question. line from Our the with Cantor proceed Please

questions. for good I which you is I get looks fourth thanks quarter. patient start the quarter. had growth quarter you know earlier morning, lower a July, wanted follow-up about can guys in back that think obviously trending in to you and on Hey, third second It you and like than XXX forms. ask mentioned

to that follow-up So got a I can IP. us help with you expecting when then on just plan? you’re see growth And

Yes. an quarter. as I the sort clear driving we numbers we’re this listen, we’re see – It’s in October, to expecting – we’re down we trend. and our August organization, and the these increased see the September, through intensity the to to of get throughout back growth putting sales initiatives December with on need

through the the say So now all year. I end of the way QX would the into

of price a very and because have So have And combination have it’s that’s that. retention. I that, you have patient to short net on that reinforce have to you top solid to the not trend, just growth But to I mean want have of solid answer. PSF a you

we and all should just be reported. to through evidenced quarter that be together have working they So the

guys extend Okay, matter? composition on have And additional of got Thank XXXX get And beyond IP we those? patents us that you remind what on and also it. when other levers updates pull could can IP, you. could you that your then to

of [ph] USPTO patient adjusting terms AURA in observation actually in of on terms both and in improvement response based upon saw AURORA dose based their been that’s of is to we response. by the which We the Well, issued the already years a challenge, that’s issued patent the the you of was know, question our the that that first relative was one couple all downwards when patent lowering proteinuria. eGFR saw the IPR ago in XXX where is

So all that patent way the XXXX. goes to

file we In patents I patents talk filings and around more additional these as patent, these have. fencing think about as the USPTO that we we we’ll addition But ring to that the of more with closer on currently that would get issue. strategies as have

as well we’re and looking active patents conversation be might the able at that. through generation that we’re et to patent So formulations, this on of those we course, where real, data new But in it we’ve either can talk unique and could about the know And different filings either it bolster filed file. exploring in we are or conversations, we’re as able different when motion constantly only both data at cetera, help becomes – looking generated to or that stage. of

all we So and the through our intend IPR we’ll strategy execute to we to keep our options see open continue defend as and IP. on

Okay, great. Thanks very much.

Thanks, Olivia.

line question Please next of RBC. comes your Sahil from Dhingra with the Our question. with proceed

please in comment you understand of improvement have for you might low have Dhingra QX – I this Miehm. questions. QX? refill refill rates because Could [indiscernible] for improved rates taking and refill versus rates? have there the is is Omicron also on might any the and the Hi, QX it was in Doug Sahil Thank

the improvement I sorry, what, get didn’t I’m sorry. I’m in Improvement,

rates. Refill

Refill anything wise can rates. I know listen, you don’t Joe, can, mean, I if Yes, on. we trend there’s comment

ensuring then And business new we that example stay multiple rates product. on that of growing where I this refill patients an were that’s and in retaining has think bringing the better. it’s right. patients, yes. It’s dose the of parameters, the they have Our right And

So patients. good education I our of that’s think

We do continue have that. to to

I patients new through office sort Joe, attack of more up and ensuring all of Six got. way retention in we these add a refill alliance patients physician through points follow the you Aurinia to with that and any to we’ve the rates? color on driving prescriptions to can Sigma both we that trying need think and ensure

we quarter. of as Yes, mentioned, we highest to shipped number wallets the this date past

we’re average, think are of a rates on pretty good. per patient those seeing still I from So number wallets

dose We haven’t of coming seen play into too kind adjustments often.

And bleed we in average patient per kind you’re of month. per refill are number seeing are through of shipping strong our So rates patient. the that per wallets

That’s much. so fine. you Thank

to hand call in closing There queue. are the I’d remarks. management to like no back for further the questions

much. you the thank want everyone in and us to today. you forward very joining next upcoming to I look updating We for months Thank quarter.

teleconference. Ladies your and you Thank conclude for this participation. today’s does gentlemen,

You lines day. and may your a time disconnect this have at wonderful